亚盛医药-B2024年中期报告

（於開曼群島註冊成立的有限公司）股份代號：6855 2024中期報告 2111213153466676869717273 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 68 202467David Sidransky 9517B FCPA, FCG (CS, CGP), HKFCG (CS, CGP) 1 202467202467 Wilson Sonsini Goodrich & Rosati1151509 202467202467202467 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 202467David Sidransky202467 1617 97927 6855 www.ascentage.cn •20246302023630142.7681.0477.2%823.72024630 •2024630202363017.00.31.8%17.3(i)(ii) •202363083.36.37.6%202463089.6® •2023630309.8134.343.4%2024630444.1 •2024630202363091.34.34.7%87.0 •20246307.120236304.22.969.0% •20246302023630402.3565.1162.8 •20246301,100.3202312311,093.86.50.6%20247100.0 •2024630®(HQP1351)BCR-ABL202111489.72024®2023120%5%2024630®202379%®20247(ISAF)(TKI)T315I(CML)(-CP)(-AP)TKICML-CP •20246TakedaPharmaceuticals International AG®®1®122024721 •2024624,307,32275,000,000585.77 •20245(NMPA)(CDE)(succinatedehydrogenase,SDH)(gastrointestinalstromal tumor,GIST)III(POLARIS-3)20242FDA(CML-CPT315IIII(POLARIS-2) •lisaftoclax(APG-2575)(NMPA)(CDE)APG-2575MDSIII(GLORA-4) •202462024(EHA2024)®2024660(ASCO)TKISDHGIST202442024(AACR)SDH •20246EHA2024APG-2575(R/R)(MM)(AL)2024660(ASCO)APG-2575(WM)Ib/IIAPG-2575(AZA)(TN)(R/R)(AML)Ib/II •202432024(Multidisciplinary Head and Neck Cancers Symposium)1/2alrizomadlin (APG-115)(adenoid cystic carcinoma, ACC) •60(ASCO)APG-2449(NSCLC)APG-2449ASCO20246EHA2024APG-5918APG-5918(CKD)(HB)202442024(AACR)APG-5918alrizomadlin (APG-115)(PCa) •(FDA)(EC)(RPD)(ODD) •2024GMP BCR-ABL1ALKFAKEEDBcl-2Bcl-2/Bcl-xLIAPMDM240I/II ®BCR-ABL1T315ICMLBCR-ABLT315I(CML)(-CP)(-AP)TKICML-CP®20246TakedaPharmaceuticals International AG®® 2024630520367Dana-FarberMD 62024630 (1)II2024NDA (2)CLL/SLLAMLMDSMM2 (3)FDA (4) ® ®®T315ICML-CPBCR-ABL1(TKI)®®202312022 ®2024(NCCN) CML(CSCO)CMLPh+ALL®FDACML(AML)(ALL)(GIST)(ODD)(FTD)TKICML®EMA ® •20247®(ISAF)(TKI)T315I(CML)(-CP)(-AP)TKICML-CP •20245®2024CSCO(CML)(Ph+ ALL)•2023122024(NCCN)(CML) •20245(NMPA)(CDE)(succinatedehydrogenase,SDH)(gastrointestinalstromal tumor,GIST)III(POLARIS-3)•20242FDA(CML-CPT315IIII(POLARIS-2) •20246®2024(EHA2024)®(CML)(Ph+ALL)1TKIponatinibasciminibT315I® •2024660(ASCO)®TKI(SDH-)(GIST)SDHGISTASCO •202442024(AACR)SDH ®2024 •(CML)III(POLARIS-2)(Ph+ ALL)(POLARIS-1)SDHGISTIII(POLARIS-3) •TKICML-CP20242025 Lisaftoclax (APG-2575) Lisaftoclax(APG-2575)Bcl-2Bcl-22024(NMPA)(CDE)lisaftoclax(CLL/SLL)NDACLL/SLLNDABcl-2lisaftoclax(APG-2575)21Ib/II(CLL/SLL)(NHL)(AML)(MM)(WM)20246301,000lisaftoclax (APG-2575)400CLL/SLLlisaftoclax (APG-2575)FDA(FL)(WM)(CLL)(MM)AML lisaftoclax (APG-2575) •lisaftoclax (APG-2575)(NMPA)(CDE)lisaftoclax(APG-2575)MDSIII(GLORA-4)•lisaftoclax(APG-2575)(AML)III(GLORA-3)•lisaftoclax(APG-2575)(BTK)III(CLL/SLL)CLL/SLL(GLORA-2)•lisaftoclax(APG-2575)BTKBTKCLL/SLLIII(GLORA)•Lisaftoclax (APG-2575)AML/MDSIb/II•Lisaftoclax (APG-2575)AML/MDSIb/II •Lisaftoclax (APG-2575)MMIb/II •Lisaftoclax (APG-2575)MMIb/II •Lisaftoclax(APG-2575)BTKWMIb/II •202462024(EHA2024)lisaftoclax(R/R)(MM)(AL)Alisaftoclax27r/r MM10(PR)7(VGPR)2(CR)ORR70.4%314.3% •2024660(ASCO)lisaftoclax(WM)Ib/IIlisaftoclax(APG-2575)ASCOlisaftoclax(AZA)AML(R/R)(AML)Ib/II39AMLORR(CRc)64.1%51.3%10.5%TLS30601.3%3.9% lisaftoclax (APG-2575)2024 •2024CLL/SLL •GLORAGLORA-2GLORA-3GLORA-4 18A.08(3)LISAFTOCLAX (APG-2575) Alrizomadlin (APG-115) Alrizomadlin (APG-115)MDM2-p53 PPIMDM2-p53p53alrizomadlin(APG-115) Alrizomadlin (APG-115)FDAAMLIIB-IVAlrizomadlin(APG-115)FDA alrizomadlin (APG-115) alrizomadlin (APG-115) •alrizomadlin(APG-115)Ib/II•alrizomadlin(APG-115)(azacitidine)AML(CMML)MDSIb/II•alrizomadlin (APG-115)APG-2575T(R/R T-PLL)(NHL)IIA•alrizomadlin (APG-115)II CDEalrizomadlin (APG-115) •alrizomadlin(APG-115)PD-1(JS001(LPS)Ib/II•alrizomadlin(APG-115)AMLMDSIb•alrizomadlin(APG-115)lisaftoclax(APG-2575)I •2024320241/2APG-115(adenoid cystic carcinoma, ACC)•202442024(AACR)APG-115APG-5918(PCa)•20246 18A.08(3)ALRIZOMADLIN (APG-115) Pelcitoclax (APG-1252) P e l c i t o c l a x( A P G -1252)B c l -2B c l - x L(SCLC)(NSCLC)(NET)(NHL)APG-1252FDASCLC 20231220203pelcitoclax (APG-1252)Pelcitoclax(APG-1252) pelcitoclax (APG-1252) Pelcitoclax (APG-1252) •pelcitoclax (APG-1252)(EGFR)NSCLCIb•pelcitoclax (APG-1252)Ib•pelcitoclax(APG-1252)(NHL)Ib/II •20242Pelcitoclax 18A.08(3)PELCITOCLAX (APG-1252) APG-5918 APG-5918(EED)2(PRC2)APG-5918(CKD)(HB) FDAAPG-5918IAPG-5918 APG-5918 •202462024(EHA2024)APG-5918APG-5918(CKD)(HB)•202442024(AACR)APG-5918alrizomadlin (APG-115)(PCa)•20231APG-5918CDE 18A.08(3)APG-5918 APG-2449 APG-2449FAK/ALK/ROS1(TKI)ALKALKEML4-ALKL1196MBa/F3APG-2449ALK(P-ALK)APG-2449ALKALK TKI APG-2449 •2024660(ASCO)APG-2449(NSCLC)APG-2449ASCOAPG-2449TKI2ALK TKINSCLC•202442024(AACR)APG-2449(EOC)(PLD)•APG-2449Ib/II 18A.08(3)APG-2449 (PK/PD) (TPD)p53-MDM220MDM2p53alrizomadlinp53MDM2MDM2 Bcl-xLBcl-xLBcl-xLBcl-xL 2024630309.8444.1 2024630520367 2024630®2024112.92100(1801.HK)117800